Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Endocrine 1CNS 1

Conditions

Multiple Myeloma 50Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Recurrence 9Burkitt Lymphoma 7Neoplasms, Plasma Cell 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma 5Immunoglobulin Light-chain Amyloidosis 5Hodgkin Disease 4Lymphoma, T-Cell 3Lymphoma, Non-Hodgkin 3Lymphoma, B-Cell 3Leukemia 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Oligodendroglioma 2Neoplasms 2Neoplasm Metastasis 2Mesothelioma 2Lymphoma, T-Cell, Cutaneous 2Leukemia, Myeloid, Acute 2Leukemia, Hairy Cell 2Leukemia, Biphenotypic, Acute 2Hematologic Neoplasms 2Glioblastoma 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Astrocytoma 2Amyloidosis 2Waldenstrom Macroglobulinemia 1Vascular Diseases 1Uveal Melanoma 1

Interventions

Dexamethasone 1Calcium Dobesilate 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Adenoma, Acidophil × Calcium Dobesilate × Clear all
NCT01088763 2014-11-05

Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia

National Cancer Institute (NCI)

Phase 1 Terminated
129 enrolled
CNSEndocrineLymphoidOther hematologic neoplasmSarcoma

Familial ependymoma, Adenoma, Basophil, Adenoma, Chromophobe, Adenoma, Acidophil, Astrocytoma, Burkitt Lymphoma, Medulloblastoma, Oligodendroglioma, Pituitary Neoplasms, Recurrence, Spinal Cord Neoplasms, Prolactinoma, Choroid Plexus Neoplasms, Lymphoma, Large-Cell, Anaplastic, Rhabdoid Tumor, Optic Nerve Glioma, Leukemia, Large Granular Lymphocytic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡